Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806

Journal of Nuclear Medicine

Volumn 51, Issue 6, 2010, Pages 967-972

  Lee, Fook T ^a,b   O'Keefe, Graeme J ^c   Gan, Hui K ^a   Mountain, Angela J ^a   Jones, Gareth R ^c   Saunder, Timothy H ^c   Sagona, Jessica ^c   Rigopoulos, Angela ^a   Smyth, Fiona E ^a   Johns, Terrance G ^a,b   Govindan, Serengulam V ^d   Goldenberg, David M ^e   Old, Lloyd J ^a,f   Scott, Andrew M ^a,b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HOSPITAL   (Australia)

^d IMMUNOMEDICS INC   (United States)

^e GARDEN STATE CANCER CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Glioma; Monoclonal antibody; Mutant epidermal growth factor receptor; PET

Indexed keywords

CHIMERIC ANTIBODY; CHIMERIC ANTIBODY CH806; EPIDERMAL GROWTH FACTOR RECEPTOR; IODINE 124; PEPTIDE; PEPTIDE IMP R4; UNCLASSIFIED DRUG; 4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBONYLLYSYL(4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBONYL) LYSYL(1 ((4 THIOCARBONYLAMINO)BENZYL)DIETHYLENETRIAMINEPENTAACETIC ACID) TYROSYL LYSINE(1 ((4 THIOCARBONYLAMINO)BENZYL)DIETHYLENETRIAMINEPENTAACETIC ACID); 4-(N-MALEIMIDOMETHYL)CYCLOHEXANE-1-CARBONYLLYSYL(4-(N-MALEIMIDOMETHYL)CYCLOHEXANE-1-CARBONYL)-LYSYL(1-((4-THIOCARBONYLAMINO)BENZYL)DIETHYLENETRIAMINEPENTAACETIC ACID)-TYROSYL-LYSINE(1-((4-THIOCARBONYLAMINO)BENZYL)DIETHYLENETRIAMINEPENTAACETIC ACID); DIAGNOSTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; OLIGOPEPTIDE; PENTETIC ACID; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLIOMA; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; CELL TRANSFORMATION; COMPUTER ASSISTED TOMOGRAPHY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; RADIOGRAPHY; SCINTISCANNING; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IODINE RADIOISOTOPES; MICE; OLIGOPEPTIDES; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953924458     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.068395     Document Type: Article

References (40)

1. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313-1319.
2. Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med. 2005;46(suppl 1):164S-171S.
3. 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med. 2001;42:764-769.
4. Lee FT, Scott AM. Immuno-PET for tumor targeting. J Nucl Med. 2003;44:1282-1283.
5. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005;23:2445-2459.
6. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA. 1990;87:8602-8606.
7. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol. 1998;4:148-158.
8. Johns TG, Adams TE, Cochran JR, et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem. 2004;279:30375-30384.
9. Jungbluth AA, Stockert E, Huang HJ, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA. 2003;100:639-644.
10. Panousis C, Rayzman VM, Johns TG, et al. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer. 2005;92:1069-1077.
11. Luwor RB, Johns TG, Murone C, et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res. 2001;61:5355-5361.
12. Mishima K, Johns TG, Luwor RB, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 2001;61:5349-5354. (Pubitemid 32694908)
13. Johns TG, Stockert E, Ritter G, et al. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer. 2002;98:398-408.
14. Perera RM, Narita Y, Furnari FB, et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res. 2005;11:6390-6399.
15. Perera RM, Zoncu R, Johns TG, et al. Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia. 2007;9:1099-1110.
16. Scott AM, Lee F-T, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA. 2007;104:4071-4076.
17. 131I for use in radioimmunotherapy. J Nucl Med. 2005;46:153-159.
18. Scott AM, Lee FT, Jones R, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res. 2005;11:4810-4817.
19. Penefsky HS. A centrifuged-column procedure for the measurement of ligand binding by beef heart F1. Methods Enzymol. 1979;56:527-530.
20. Vaidyanathan G, Bigner DD, Zalutsky MR. Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography. J Nucl Med. 1992;33:1535-1541.
21. Schuhmacher J, Kaul S, Klivenyi G, et al. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res. 2001;61:3712-3717.
22. 68Ga-radiolabeled bivalent haptenpeptide-chelate conjugates. J Nucl Med. 2004;45:30-39.
23. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701-706.
24. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007;34:850-858.
25. Philpott GW, Schwarz SW, Anderson CJ, et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med. 1995;36:1818-1824.
26. Wu AM, Yazaki PJ, Tsai S, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Nat Acad Sci USA. 2000;97:8495-8500.
27. 3. Cancer Res. 2006;66:9673-9681.
28. 111In radiolabels. J Nucl Med. 2001;42:1281-1287.
29. 111In labeled Herceptin. Nucl Med Biol. 2002;29:599-606.
30. Lovqvist A, Sundin A, Ahlstrom H, Carlsson J, Lundqvist H. Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. J Nucl Med. 1997;38:395-401.
31. 76Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin. J Nucl Med. 2007;48:1172-1179.
32. 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm. 2004;19:155-163.
33. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002;94:1484-1493.
34. 124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304-310.
35. 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med. 2003;44:1663-1670.
36. 177Lu in tumorbearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med. 2005;46:1898-1906.
37. 90Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:1337-1345.
38. Borjesson PK, Jauw YW, Boellaard R, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133-2140.
39. Johns TG, Perera RM, Vernes SC, et al. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res. 2007;13:1911-1925.
40. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991;83:97-104.